|1.||Itoh, Kyogo: 5 articles (02/2009 - 02/2004)|
|2.||Shichijo, Shigeki: 4 articles (02/2009 - 02/2004)|
|3.||Takedatsu, Hiroko: 4 articles (04/2007 - 02/2004)|
|4.||Noguchi, Masanori: 3 articles (02/2009 - 10/2005)|
|5.||Matsueda, Satoko: 2 articles (04/2007 - 10/2005)|
|6.||Sasada, Tetsuro: 2 articles (04/2007 - 04/2004)|
|7.||Harada, Mamoru: 2 articles (04/2007 - 10/2005)|
|8.||Azuma, Koichi: 2 articles (04/2007 - 04/2004)|
|9.||Zhang, Wenlu: 1 article (01/2013)|
|10.||Liu, Xiaohui: 1 article (01/2013)|
02/01/2004 - "One RLI- or KIAA0036-derived peptide induced tumor-reactive CTLs in PBMCs of HLA-A3(+) and -A11(+) or HLA-A11(+) and -A33(+) cancer patients also with various frequencies (22-67%), respectively, whereas the other peptide induced CTL activity in only HLA-A33(+) patients. "
04/15/2004 - "Three IEX-1-derived peptides at positions 47-56, 61-69, and 65-73, which were recognized by the 850B-CTLs, could induce CD8(+) peptide-specific CTL reaction to tumor cells from HLA-A33(+) gastric cancer patients and other epithelial cancer patients, but not from healthy donors, in an HLA class I-restricted manner. "
04/15/2004 - "Because increased expression of IEX-1 is suggested to be involved in the resistance to apoptosis and in the proliferation of cancer cells, these antigenic peptides could be potent candidates for peptide-based specific immunotherapy against HLA-A33(+) gastric cancer and other epithelial cancers."
11/01/1998 - "This protein has been identified as a melanoma antigen recognized by tumor reactive CTLs derived from tumor infiltrating lymphocytes in the context of HLA-A31 and HLA-A33. "
04/01/2007 - "Together with our previous findings, these results indicate that the 2 IEX peptides could be appropriate vaccine candidates for HLA-A11, HLA-A31, and HLA-A33 positive epithelial cancer patients. "
06/01/1998 - "In Japanese men with idiopathic azoospermia the frequency of HLA-A33, B13 and B44 was significantly increased compared with controls. "
07/01/1999 - "We previously reported that the HLA-A33, -B13, and -B44 antigens, which are major histocompatibility complex class I molecules, are involved in the susceptibility of nonobstructive azoospermia in Japanese men. "
|3.||Prostatic Neoplasms (Prostate Cancer)
02/01/2009 - "This peptide induced cancer cell-reactive cytotoxic T lymphocytes from peripheral blood mononuclear cells of both healthy donors and prostate cancer patients with HLA-A11, HLA-A31 and HLA-A33 alleles, but not with HLA-A2. "
10/01/2005 - "These peptides efficiently induced peptide-specific and prostate cancer-reactive CTLs from PBMCs of cancer patients with the HLA-A11, HLA-A31, and HLA-A33 alleles. "
10/01/2005 - "These peptides were first screened for their ability to be recognized by immunoglobulin G (IgG) of prostate cancer patients and subsequently for the potential to induce peptide-specific and prostate cancer-reactive CTLs from peripheral blood mononuclear cells (PBMC) of cancer patients with the HLA-A11, HLA-A31, and HLA-A33 alleles. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|4.||HLA-A3 Antigen (HLA A3 Antigen)
|5.||HLA-B35 Antigen (HLA B35 Antigen)
|6.||HLA-A2 Antigen (HLA A2 Antigen)
|8.||HLA-A Antigens (HLA-A)
|10.||Immunoglobulin G (IgG)